<SEC-DOCUMENT>0001144204-18-047690.txt : 20180904
<SEC-HEADER>0001144204-18-047690.hdr.sgml : 20180904
<ACCEPTANCE-DATETIME>20180904071916
ACCESSION NUMBER:		0001144204-18-047690
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180831
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180904
DATE AS OF CHANGE:		20180904

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		181051247

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv502211_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
September 4, 2018 (August 31, 2018)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Applied
DNA Sciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Delaware</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction<BR>
        of incorporation)</P></TD>
    <TD STYLE="width: 34%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-36745</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="width: 33%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>59-2262718</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>50 Health Sciences Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stony Brook, New York 11790</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices;
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>631-240-8800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter). Emerging growth company
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01 Entry into a Material Definitive Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2018, Applied DNA Sciences,
Inc. (the &ldquo;Company&rdquo;) entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with the purchasers
named therein, including the Company&rsquo;s chairman, president and chief executive officer, certain members of the Board of Directors
and management team, and certain other accredited investors (the &ldquo;Purchasers&rdquo;), pursuant to which the Company issued
and sold to the Purchasers an aggregate of $1.65 million in principal amount of secured convertible notes (the &ldquo;Notes&rdquo;)
bearing interest at a rate of 6% per annum (the &ldquo;Private Placement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notes are convertible, in whole or
in part, at any time, at the option of the Purchasers, into shares of the Company&rsquo;s Common Stock, $0.001 par value per share
(&ldquo;Common Stock&rdquo;), in an amount determined by dividing the principal amount of each Note, together with any and all
accrued and unpaid interest, by the conversion price of $2.50. The Company has the right to require the Purchasers to convert all
or any part of their Notes into shares of the Company&rsquo;s Common Stock at a conversion price of $2.50 if the price of the Common
Stock remains at a closing price of $3.50 or more for a period of twenty consecutive trading days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon any Change in Control (as defined
in the Notes), the Purchasers have the right to require the Company to redeem the Notes, in whole or in part, at a redemption price
equal to such Notes&rsquo; outstanding principal balance plus accrued interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notes contain certain events of default
that are customarily included in financing of this nature. If an event of default occurs, the Purchasers may require the Company
to redeem the Notes, in whole or in part, at a redemption price equal to such notes&rsquo; outstanding principal balance plus accrued
interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notes bear interest at the rate of
6% per annum, payable semi-annually in cash or in kind, at the Company&rsquo;s option, and are due and payable in full on August
30, 2021. Until the principal and accrued but unpaid interest under the Notes is paid in full, or converted into shares of common
stock pursuant to their terms, the Company&rsquo;s obligations under the Notes will be secured by a lien on substantially all assets
of the Company and the assets of APDN (B.V.I.) Inc., the Company&rsquo;s wholly-owned subsidiary (&ldquo;APDN BVI&rdquo;), in favor
of CSC Corporation, as Collateral Agent for the Purchasers pursuant to security agreements dated as of the date of the Purchase
Agreement (the &ldquo;Security Agreements&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also entered into a registration
rights agreement, dated as of the date of the Purchase Agreement (the &ldquo;Registration Rights Agreement&rdquo;), with the Purchasers,
pursuant to which the Company has agreed to prepare and file a registration statement with the Securities and Exchange Commission
(the &ldquo;SEC&rdquo;) to register under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) resales from
time to time of the Common Stock issued or issuable upon conversion or redemption of the Notes. The Company is required to file
a registration statement within 60 days of receiving a demand registration request from holders of a majority of the outstanding
principal balance of the Notes, and to cause the registration statement to be declared effective within 45 days (or 90 days if
the registration statement is reviewed by the SEC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Private Placement was completed in
reliance upon the exemption from registration provided for by Section 4(a)(2) of the Securities Act and by Rule 506 of Regulation
D promulgated under the Securities Act. Each of the Purchasers represented to the Company in the Purchase Agreement that it is
an &ldquo;accredited investor&rdquo; as that term is defined in Rule 501 of Regulation D. This Current Report on Form 8-K shall
not constitute an offer to sell, the solicitation of an offer to buy, nor shall there be any sale of these securities in any state
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of
any such state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The respective descriptions of the Purchase
Agreement, Note, Security Agreements and Registration Rights Agreement herein are brief summaries only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.03 Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a Registrant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information set forth in Item 1.01 above is incorporated
by reference into this Item 2.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.02. Unregistered Sales of Equity Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information set forth in Item 1.01 above is incorporated
by reference into this Item 3.02.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 4, 2018, the Company issued
a press release announcing the Private Placement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information related to the press release
furnished pursuant to this Item 1.01, including Exhibit 99.1, shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities under
that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of
1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<I>d) Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font-size: 10pt"><A HREF="tv502211_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="width: 94%; font-size: 10pt; text-align: justify"><A HREF="tv502211_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of Applied DNA Sciences, Inc. dated September 4, 2018 regarding the private placement.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: September 4, 2018</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLIED DNA SCIENCES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="width: 92%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><A HREF="tv502211_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; font-size: 10pt; text-align: justify"><A HREF="tv502211_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of Applied DNA Sciences, Inc. dated September 4, 2018 regarding the private placement.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv502211_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Applied DNA Announces Closing of $1.65 Million
Private Placement of Secured Convertible Notes<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>STONY BROOK, N.Y., September 4, 2018</B> &ndash;Applied DNA
Sciences Inc., (NASDAQ: APDN, &ldquo;Applied DNA&rdquo; or the &ldquo;Company&rdquo;), the leader in large-scale PCR-based DNA
manufacturing, today announced the closing in the amount of $1.65 million of secured convertible notes (the &ldquo;Notes&rdquo;)
by way of a non-brokered private placement with accredited investors and certain members of its management team and Board of Directors,
led by its Chairman, President and Chief Executive Officer. The Company expects to use the proceeds for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;This investment enhances our balance sheet and supports
our pursuit of pre-commercial revenue opportunities in the synthetic textile, pharmaceutical and legal cannabis markets that we
believe will further diversify our revenue streams beyond our core cotton market. Having demonstrated success in penetrating large
and developing markets with substantial issues with supply chain security, such as the U.S. cotton supply chain, our growing penetration
of non-commodity markets offer a path to revenue growth,&rdquo; said Dr. James A. Hayward, chairman, president and chief executive
officer of Applied DNA. &ldquo;I want to thank the participating members of the management team, Board of Directors and outside
investors for their very strong vote of confidence in the Company&rsquo;s vision, growth strategy and market opportunity.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Notes were issued on August 31, 2018, mature on August 30,
2021, and, carry a coupon of 6.00%, payable semi-annually either in cash, or in kind. Each Note, including interest, is convertible
at the option of the holder at any time prior to maturity into shares of Common Stock at a conversion price of $2.50 per share.
The Company has the right to require the holders of the Notes to convert the Notes, including interest, into shares of Common Stock
at a conversion price of $2.50 per share in the event that the Company&rsquo;s closing share price exceeds $3.50 for 20 consecutive
trading days. The Notes will be secured by substantially all assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Applied DNA Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Applied DNA is a provider of molecular
technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass
production for diagnostics and therapeutics.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Applied DNA makes life real and safe
by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply
chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The
proprietary DNA-molecular based &ldquo;CertainT<SUP>&reg;</SUP>&rdquo; platform can be used to identify, tag, test, and track products,
to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature<SUP>&reg;</SUP>&nbsp;DNA describes
the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature<SUP>&reg;</SUP>&nbsp;T
and fiberTyping<SUP>&reg;</SUP>, targeted toward textiles and apparel, BackTrac&trade; and DNAnet<SUP>&reg;</SUP>, for anti-theft
and loss prevention, and digitalDNA<SUP>&reg;</SUP>, providing powerful track-and-trace. All provide a forensic chain of evidence,
and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences
using the polymerase chain reaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Visit&nbsp;<U>adnas.com</U>&nbsp;for
more information. Follow us on&nbsp;<U>Twitter</U>&nbsp;and&nbsp;<U>LinkedIn</U>. Join our&nbsp;<U>mailing list</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company&rsquo;s Common Stock and
warrants are listed on the NASDAQ Capital Market under the symbols APDN and APDNW, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The statements made by
Applied DNA in this press release may be &quot;forward-looking&quot; in nature within the meaning of the Private Securities Litigation
Act of 1995.&nbsp;Forward-looking&nbsp;statements describe Applied DNA&rsquo;s future plans, projections, strategies and expectations,
and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA.
Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited
market acceptance, shifting enforcement priorities of US federal laws relating to cannabis, and various other factors detailed
from time to time in Applied DNA's SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017
and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available
at&nbsp;www.sec.gov</FONT><FONT STYLE="background-color: white">. APDN undertakes no obligation to update publicly any&nbsp;</FONT>forward<FONT STYLE="background-color: white">-</FONT>looking<FONT STYLE="background-color: white">&nbsp;statements
to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless
otherwise required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>investor contact: </B>Sanjay M. Hurry, LHA Investor Relations,
212-838-3777, shurry@lhai.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>web:&nbsp;</B>www.adnas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>twitter: </B>@APDN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L LX# 2(  A$! Q$!_\0
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M6",[2<NW0<4TFW9";25V7:***0PHHHH ***CCGBE:18Y4=HVVN%8$J?0^AH
MDHHHH **** "BBB@ HK*\0>(M,\,Z8U_JEP(H@<*H&7D;^ZH[FO#_$_Q4\2:
MY!(^FQ3:7I6[9YL2DNQ]&DZ ^P_,T >V:WXLT+PZI.J:G! ^,B+=ND/T49/Z
M55\*>-M)\8B\.F"X'V1E5_.CVY#9P1R>.#[UXKX)TGP)J<JR^(=;N#>N<M!/
MF&,GWDR=WYBO;O"NG0:;9S16FGV=I:E\Q&U Q(/4D$[N,<F@#?HHHH ****
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M_P#SPE_[]FJY:?9?@3S3[LLG7=5_Y_I?T_PIIU[5?^?Z7]/\*K&VG_Y]YO\
MOV:8;:X_Y]YO^_9JN2GV7X"YY]W^):.O:MC_ (_Y?T_PII\0:M_S_P OZ?X5
M5-M<8_X]YO\ OV?\*8;:X_Y]YO\ OV?\*?)3[+\"7.IW?XEL^(-7_P"@A-^G
M^%-/B'6/^@A-^G^%5#:W'_/O-_W[/^%,-K<?\^\W_?L_X4^2GV7X"YZG=_B7
M#XBUC_H(S?I_A3#XCUG_ *",WZ?X54-K<_\ /M-_W[/^%,-K<_\ /M/_ -^V
M_P *KDI=E^ G.IW?XEP^)-9_Z",WZ?X4T^)=:Q_R$IOT_P *IFTN?^?:?_OT
MW^%,-I<X_P"/:?\ []-_A5<E+LOP)YZG=_B7#XFUO_H)3_I_A2'Q-K?_ $$Y
M_P!/\*HFTNO^?6?_ +]-_A33:77_ #ZS_P#?IO\ "GR4NR_ 3G5[O\2Z?$^N
M?]!.?]/\*:?%&N_]!.?]/\*HFSNO^?6?_OTW^%--G=?\^MQ_WZ;_  JO9TNR
M_ GGJ]W^)>/BG7?^@I/^G^%-/BK7O^@I/^G^%4#9W?\ SZ7'_?IO\*:;.[_Y
M]+C_ +]-_A3]G1[+\!.I5[O\2^?%>O\ _05G_P#'?\*8?%FO_P#05N/_ !W_
M  J@;*[_ .?2X_[]-_A3#97?_/I<?]^6_P *KV='LOP)]I5[O\31/BSQ!_T%
MKC_QW_"F'Q;X@_Z"UQ_X[_A5 V5Y_P ^=S_WY;_"F-97G_/G<_\ ?EO\*:IT
M>R_ 3J5>[_$T#XN\0_\ 06N/_'?\*:?%_B+_ *"]Q_X[_A6<;&\_Y\[G_ORW
M^%--C>?\^=S_ -^6_P *KV='LOP%[2MW?XFB?&'B+_H+W'_CO^%-/C'Q'_T&
M+C_QW_"LXV-Y_P ^=S_WY;_"F&QO?^?*Y_[\M_A3]G0[+\"74K=W^)HGQEXD
M_P"@Q<_^._X4A\9^)/\ H,W/_CO^%9AL+W_GRNO^_+?X4TV%[_SY77_?EO\
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M+]9\07L>K>.+V>0 #;:M+ND8=@Q'"CV'/TKV&""*VMXX((UBAC4(B(,!0.@
MJ2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
